Advanced glycation end products, measured as skin autofluorescence and diabetes complications: A systematic review

Diabetes Technology and Therapeutics

Volumn 13, Issue 7, 2011, Pages 773-779

  Bos, Dieuwke C ^a   De Ranitz Greven, Wendela L ^a   De Valk, Harold W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT;

ANALYTICAL EQUIPMENT; AUTOFLUORESCENCE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

ANIMALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MORTALITY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SKIN; SPECTROMETRY, FLUORESCENCE;

EID: 79959656594     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2011.0034     Document Type: Review

References (29)

1. Fox CS, Pencina MJ, Meigs JB, Vasan RS, Levitzky YS, D'Agostino RB Sr: Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study. Circulation 2006;113:2914-2918 (Pubitemid 44297232)
2. Winer N, Sowers JR: Epidemiology of diabetes. J Clin Pharmacol 2004;44:397-405 (Pubitemid 38396785)
3. Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ: Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am 2010;39:481-497
4. Monnier VM: Nonenzymatic glycosylation, the Maillard reaction and the aging process. J Gerontol 1990;45:B105-B111 (Pubitemid 20224052)
5. Miyata T, van Ypersele de SC, Kurokawa K, Baynes JW: Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 1999;55:389-399 (Pubitemid 29082866)
6. Singh R, Barden A, Mori T, Beilin L: Advanced glycation end-products: a review. Diabetologia 2001;44:129-146 (Pubitemid 32156196)
7. Schmidt AM, Hasu M, Popov D, Zhang JH, Chen J, Yan SD, Brett J, Cao R, Kuwabara K, Costache G, Simionescu N, Simionescu M, Stern D: Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci U S A 1994;91:8807-8811
8. Koetsier M, Lutgers HL, de Jonge C, Links TP, Smit AJ, Graaff R: Reference values of skin autofluorescence. Diabetes Technol Ther 2010;12:399-403
9. Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, Lee A, Al-Abed Y, Vlassara H, Bucala R, Cerami A: Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A 1997;94:13915-13920 (Pubitemid 28009684)
10. Greven WL, Smit JM, Rommes JH, Spronk PE: Accumulation of advanced glycation end (AGEs) products in intensive care patients: an observational, prospective study. BMC Clin Pathol 2010;10:4
11. Noordzij MJ, Lefrandt JD, Smit AJ: Advanced glycation end products in renal failure: an overview. J Ren Care 2008;34:207-212
12. Gerrits EG, Smit AJ, Bilo HJ: AGEs, autofluorescence and renal function. Nephrol Dial Transplant 2009;24:710-713
13. Beisswenger PJ, Makita Z, Curphey TJ, Moore LL, Jean S, Brinck-Johnsen T, Bucala R, Vlassara H: Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 1995;44:824-829
14. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991;325:836-842
15. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thorpe SR, Baynes JW, Lyons TJ: Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 1993;91:2470-2478 (Pubitemid 23182498)
16. Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, Sivitz W, Monnier VM; DCCT Skin Collagen Ancillary Study Group: Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications participants with type 1 diabetes. Diabetes 2005;54:3103-3111 (Pubitemid 43334362)
17. Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Hanssen KF, Laakso M: Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia 2007;50:1409-1417 (Pubitemid 46879016)
18. Meerwaldt R, Links T, Graaff R, Thorpe SR, Baynes JW, Hartog J, Gans R, Smit A: Simple noninvasive measurement of skin autofluorescence. Ann N Y Acad Sci 2005;1043: 290-298 (Pubitemid 41123918)
19. Meerwaldt R, Hartog JW, Graaff R, Huisman RJ, Links TP, den Hollander NC, Thorpe SR, Baynes JW, Navis G, Gans RO, Smit AJ: Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3687-3693 (Pubitemid 46211290)
20. Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, Thorpe SR, Baynes JW, Gans RO, Smit AJ: Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004;47:1324-1330 (Pubitemid 39093330)
21. Chabroux S, Canoü-Poitrine F, Reffet S, Mills-Joncour G, Morelon E, Colin C, Thivolet C: Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy. Diabetes Metab 2010;36:152-157
22. Lutgers HL, Graaff R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, Smit AJ: Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 2006;29:2654-2659 (Pubitemid 44912194)
23. Meerwaldt R, Links TP, Graaff R, Hoogenberg K, Lefrandt JD, Baynes JW, Gans RO, Smit AJ: Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. Diabetologia 2005;48:1637-1644 (Pubitemid 41175518)
24. Monami M, Lamanna C, Gori F, Bartalucci F, Marchionni N, Mannucci E: Skin autofluorescence in type 2 diabetes: beyond blood glucose. Diabetes Res Clin Pract 2008;79:56-60
25. Gerrits EG, Lutgers HL, Kleefstra N, Graaff R, Groenier KH, Smit AJ, Gans RO, Bilo HJ: Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care 2008;31:517-521
26. Lutgers HL, Gerrits EG, Graaff R, Links TP, Sluiter WJ, Gans RO, Bilo HJ, Smit AJ: Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia 2009;52: 789-797
27. Meerwaldt R, Lutgers HL, Links TP, Graaff R, Baynes JW, Gans RO, Smit AJ: Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 2007;30:107-112 (Pubitemid 46052507)
28. Goh SY, Cooper ME: Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008;93:1143-1152 (Pubitemid 351519698)
29. Turgut F, Bolton WK: Potential new therapeutic agents for diabetic kidney disease. Am J Kidney Dis 2010;55:928-940